# CPTx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cptx

- Industry: Biotechnology
- Headquarters: Planegg, Germany
- Website: www.cptx.bio/
- Total disclosed funding: $29M
- Latest round: Seed (Nov 10, 2023)
- Investors on record: 8

## About

Founded in 2021 and based in Planegg, Germany, CPTx GmbH operates as a biotechnology research company that develops biopharmaceuticals for treating rare diseases through nanotechnology and artificial intelligence. In September 2024, CPTx GmbH raised USD 29 million in venture funding co-led by investors BlueYard Capital and Sprind GmbH, with participation from other investors Leblon Capital GmbH, Bayern Capital, and aMoon. Individual investors also participated in the round. Hendrik Dietz (CEO) and Christian Sigl founded the firm.

CPTx’s primary product offering revolves around its proprietary platform that enables the creation of programmable therapeutics. These therapies are designed to offer precise drug molecule placement and polyvalent presentation, which addresses multifaceted diseases. The company’s antiviral countermeasures, in particular, aim to reduce viral loads, support immune responses, and provide biologically inert, multi-route administration options.

The September 2024 funding may enable CTx Gmbh to develop its antiviral platform further, advance its pipeline candidates, and hire additional staff.

## Funding rounds

- Seed, Nov 10, 2023, $29M — Bayern Kapital, BlueYard Capital, aMoon, ScoutFund, Leblon Capital, Renner Ventures & Philantropies GmbH, SPRIND, Inari ventures

## Investors

- Bayern Kapital (https://capitalatlas.ai/funds/bayern-kapital) — Seed
- BlueYard Capital (https://capitalatlas.ai/funds/blueyard-capital) — Seed
- aMoon (https://capitalatlas.ai/funds/amoon) — Seed
- ScoutFund (https://capitalatlas.ai/funds/scoutfund) — Seed
- Leblon Capital (https://capitalatlas.ai/funds/leblon-capital) — Seed
- Renner Ventures & Philantropies GmbH — Seed
- SPRIND — Seed
- Inari ventures — Seed